STOCK TITAN

Vanguard Realigns Reporting; PROCEPT BioRobotics (PRCT) Beneficial Ownership 0%

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

PROCEPT BioRobotics Corp ownership disclosure: The Vanguard Group filed an Amendment No. 4 to a Schedule 13G/A reporting 0 shares beneficially owned of Common Stock, representing 0%. The filing explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538, causing certain Vanguard subsidiaries and divisions to report separately; Vanguard states those units pursue the same investment strategies previously used.

The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.

Positive

  • None.

Negative

  • None.

Insights

Vanguard reports no beneficial ownership after internal reorganization.

The Schedule 13G/A lists Amount beneficially owned: 0 and Percent of class: 0%, indicating Vanguard does not claim beneficial ownership in this filing. The filing cites the January 12, 2026 internal realignment and reliance on SEC Release No. 34-39538 for disaggregation.

Implication: reported voting and dispositive powers are all 0; subsequent institutional activity will depend on separate subsidiary reports rather than this aggregated filing.

Filing documents a procedural change in beneficial ownership reporting under SEC guidance.

The disclosure explains that certain Vanguard subsidiaries will report separately and that The Vanguard Group, Inc. "no longer has, or is deemed to have, beneficial ownership" over those subsidiaries' holdings per the cited release. The statement preserves the same investment strategies but alters reporting lines.

Compliance note: readers should consult future separate filings by Vanguard subsidiaries for any holdings previously aggregated here; this filing itself reports no beneficial holdings.






74276L105

(CUSIP Number)
03/13/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/27/2026

FAQ

What does the Schedule 13G/A filed by Vanguard for PRCT state?

It states Vanguard beneficially owns 0 shares of PRCT, representing 0%. The filing cites a January 12, 2026 internal realignment and reliance on SEC Release No. 34-39538, with separate subsidiary reporting thereafter.

Why does The Vanguard Group report zero ownership for PRCT?

Because Vanguard describes an internal realignment effective January 12, 2026, after which certain subsidiaries will report separately. The filing states Vanguard no longer is deemed to have beneficial ownership of securities held by those subsidiaries.

Who signed the Schedule 13G/A amendment for PRCT and when?

The filing is signed by Ashley Grim, Head of Global Fund Administration, and dated 03/27/2026. The signature attests to the amended disclosure about beneficial ownership and reporting structure.

Does this filing indicate Vanguard sold or acquired PRCT shares?

No; the Schedule 13G/A reports an ownership position of 0 shares and explains reporting changes from an internal reorganization. It does not state any sale or acquisition transactions in this excerpt.
Procept Biorobotics Corp

NASDAQ:PRCT

View PRCT Stock Overview

PRCT Rankings

PRCT Latest News

PRCT Latest SEC Filings

PRCT Stock Data

1.41B
54.52M
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
SAN JOSE